ArticleFrontiers in endocrinology2025
Correlation between serum 25-hydroxyvitamin D levels and peripheral neuropathy in type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin D and Chronic Disorders: A Review of Metabolic and Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the correlation between serum 25-hydroxyvitamin D (25[OH]D) levels and diabetic peripheral neuropathy (DPN) in type 2 diabetes mellitus (T2DM) and to evaluate its predictive value for DPN. Methods: Participants were divided into three groups based on 25(OH)D levels: deficient, insufficient, and normal. The relationship between 25(OH)D and DPN, as well as the correlation of 25(OH)D and DPN with various indicators, was analyzed. Results: Compared to the non-DPN group (NDPN), the DPN group had significantly lower levels of 25(OH)D3 (22.10 ± 0.77 vs. 24.45 ± 0.66 ng/mL) and total 25(OH)D (23.12 ± 0.74 vs. 25.68 ± 0.67 ng/mL). In addition, significant differences were observed in body mass index (BMI), resting heart rate (RHR), triglyceride (TG), free triiodothyronine (FT3), and blood urea nitrogen (BUN) between the two groups ( Conclusion: Serum 25(OH)D levels can serve as a simple and effective screening tool to predict the occurrence of DPN in patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.